1-4 of 4
Amy Johnson, PHD
Close
Sort by
Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 890.
https://doi.org/10.1182/blood.V110.11.890.890
Published: 2007
Journal Articles

Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).

William Blum, MD, Rebecca B. Klisovic, MD, Cheryl Kefauver, RN, Amy Johnson, PHD, Mitch Phelps, James T. Dalton, David Lucas, PHD, LeNguyen Huynh, Shujun Liu, Michael R. Grever, MD, A.D. Colevas, Guido Marcucci, MD, John C. Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 4578.
https://doi.org/10.1182/blood.V108.11.4578.4578
Published: 2006
Journal Articles

OSU03012, a Novel Celecoxib Derivative, Induces Apoptosis in Multiple Myeloma Cells Independently of Caspase Activation.

Shuhong Zhang, PhD, Valerie L. White, Amy Johnson, PhD, Ching-Shih Chen, PhD, Sherif S. Farag, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 5075.
https://doi.org/10.1182/blood.V108.11.5075.5075
Published: 2006
Journal Articles

A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism.

Amy Johnson, PhD, Lisa Smith, Jiuxiang Zhu, Nyla Heerema, PhD, Sara Guster, Andrew Mone, MD, PhD, Michael Grever, MD, Ching-Shih Chen, PhD, John Byrd, MD
Journal: Blood
Blood (2004) 104 (11): 3471.
https://doi.org/10.1182/blood.V104.11.3471.3471
Published: 2004